$UNCY

Unicycive Therapeutics, Inc. disclosed in an amended Schedule 13G that Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC report beneficial ownership of 4,856,259 shares, or 9.99%, based on 27,855,257 shares outstanding as of Aug. 12, 2026. The stake includes 550,000 common shares plus conversion of Series A-3/A-4/A-5 preferred underlying warrants exercisable within 60 days.

Unicycive Therapeutics (NASDAQ:UNCY) shares rose about 2% premarket after it reported a Q2 loss of $0.06 per share versus a $0.48 consensus. Net loss was $1.7M, down from $6.5M, helped by $8.0M other income from warrant liability fair value changes. The FDA issued a Complete Response Letter for OLC, citing third-party manufacturing deficiencies; an inspection is scheduled and the company plans to resubmit. Cash: $61.4M, runway into 2027.

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing ven

Biotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).

Kirby McInerney LLP said it is investigating potential federal securities-law claims against Unicycive Therapeutics (NASDAQ:UNCY). The firm cites Unicycive’s June 30, 2026 FDA second Complete Response Letter for oxylanthanum carbonate, tied to prior manufacturing deficiencies. Unicycive shares fell about 39% from $7.70 to $4.69 that day; no lawsuit has been filed.

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001766140 0001766140 2026-06-19 2026-06-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001766140 0001766140 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who purchased securities before March 29, 2024. The investigation seeks to determine if Unicycive and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information and to assist with the investigation.

Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors of Integer Holdings Corp. (NYSE: ITGR), Molina Healthcare, Inc. (NYSE: MOH), Unicycive Therapeutics, Inc. (NASDAQ: UNCY), and WEBTOON Entertainment Inc. (NASDAQ: WBTN). Shareholders who held shares of these companies before specific dates are encouraged to contact the law office to explore options for corporate reforms and the return of funds. The investigations cite alleged misleading statements and failures to disclose material adverse facts to investors.

Grabar Law Office is investigating claims on behalf of long-term shareholders of Boston Scientific, Corcept Therapeutics, Nektar Therapeutics, and Unicycive Therapeutics regarding alleged breaches of fiduciary duty by officers and directors. The investigations stem from recent federal securities fraud class action lawsuits or emerging disclosures about company performance and regulatory issues. Shareholders who purchased shares before specific dates are encouraged to contact the law office to potentially seek corporate reforms and other remedies at no cost.